A Phase 1/2 interventional study of Phase I: X-396 (ensartinib) and Phase II: X-396 (ensartinib) in Advanced Solid Tumors and Non-small Cell Lung Cancer, sponsored by Xcovery Holdings, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Xcovery Holdings, Inc. (part of Betta Pharmaceuticals Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 14 under way, 2 of them phase 3. ensartinib · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 1/2, and was the 1st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →9 of the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Tang-Du Hospital · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Betta Pharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–75
Shanghai Pulmonary Hospital, Shanghai, China
Ages 18+
By country, each count listing its studies:
ensartinib: first FDA approval 2024 (ENSACOVE). What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 2 · Phase 4 1
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 48 across the 20 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Xcovery Holdings, Inc., one of the names counted as Betta Pharmaceuticals Co., Ltd.. Under that name alone:
Xcovery Holdings, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
45 studies in Carcinoma, Non-Small-Cell Lung by Betta Pharmaceuticals Co., Ltd.: 10 open now, 13 under way, 3 of them phase 3. Of 10 finished, 2 (20%) have results posted.
Among the 45 studies in Carcinoma, Non-Small-Cell Lung by Betta Pharmaceuticals Co., Ltd., this one is the 15th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 1/2, and was the 4th registered.
Betta Pharmaceuticals Co., Ltd.’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2009.
3 of the studies testing ensartinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05241028Hebei Medical University Fourth HospitalAdjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | 2027-02 |
| NCT04837716M.D. Anderson Cancer CenterEnsartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer | 2027-09-23 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing ensartinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Betta Pharmaceuticals Co., Ltd.’s 45 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans (the maximum tolerated dose). Once the recommended Phase 2 dose has been determined, an expansion phase will assess the preliminary anti-tumor activity of X-396 in ALK-positive non-small cell lung cancer. The study will also provide early information on how the body handles the drug (pharmacokinetics) and on the efficacy of X-396.
This is the first study of X-396 (ensartinib) in humans and the investigational drug will be given as a once or twice daily oral dose in 28 day cycles until there is disease progression or unacceptable safety issues. X-396 will be given to small groups of patients (1 - 6) at each dose level and the patients will be observed to see if there are any adverse safety effects. As long as there are no unacceptable safety issues after 28 days, the dose of X-396 will be increased for the next group of patients. This process will continue until the maximum tolerated dose (MTD) of X-396 is reached. Once the MTD is reached, up to 170 additional patients will also be given X-396 to further determine the activity of X-396 in patients with ALK-positive non-small cell lung cancer. These additional patients will be enrolled in the following expansion cohorts: ALK TKI-naïve patients, patients that progressed on crizotinib, patients that progressed on one or more 2nd generation ALK TKIs (patients may or may not have also received prior crizotinib), including patients with asymptomatic CNS metastases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed diagnosis of advanced solid tumor . Patients may be ALK TKI-naive or may have received prior crizotinib and/or second generation ALK TKIs. In addition, patients with a known ALK 1198 mutation will be allowed.
-For the expanded cohort portion of the study, patients must have NSCLC with ALK genomic alterations; however, patients will be allowed to enroll based on local FDA-approved ALK results.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation starting at 25 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops
Drug: Phase I: X-396 (ensartinib)
RP2D 225mg stratified based on prior treatment and CNS activity
Drug: Phase II: X-396 (ensartinib)
Oral, ALK inhibitor
Also known as: ensartinib
Expanded Cohort
Also known as: ensartinib
Maximum Tolerated Dose
To evaluate the safety/tolerability of X-396 (ensartinib) and determine the maximum tolerated dose (MTD) of X-396 as a single agent.
Time frame: 28 Days
Number of Participants With Preliminary Tumor Response in ALK Positive Patients at 225 mg QD
To explore the preliminary clinical tumor response after treatment with X-396 (ensartinib) given as a single agent in ALK positive patients at 225 mg QD. Subjects were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria (and CNS lesions were also assessed by modified Response Assessment in Neuro-Oncology). Assessments by CT or MRI were performed after every even cycle of treatment. All assessments were to be performed within 7 days of the scheduled day of assessment. Tumor lesions followed on physical examination must have been assessed on Day 1 of each cycle and at the End-of-Study Treatment Visit.
Time frame: 18 months
Plasma Concentrations Cmax for Day 1
To characterize the preliminary pharmacokinetics including Cmax f X-396 given as a single agent
Time frame: 24 hours
Plasma Tmax on Day 1
To characterize the preliminary pharmacokinetics including T max of X-396 given as a single agent
Time frame: 24 hours
Plasma Concentrations AUC on Day 1
To characterize the preliminary pharmacokinetics including AUC of X-396 given as a single agent
Time frame: 0, 0.5h, 1.0h , 2.0 h, 4.0h, 6.0h, 8.0h, 24.0h,
Plasma Concentrations Half-life on Day 1
To characterize the preliminary pharmacokinetics including half life of X-396 given as a single agent
Time frame: 24 hours
A total of 131 subjects were treated at 16 sites in the US, including 37 subjects in the escalation cohorts and 94 subjects in the expansion cohort.
| Milestone | Phase I: X-396 (Ensartinib) at 25 mg | Phase I: X-396 (Ensartinib) at 50 mg | Phase I: X-396 (Ensartinib) at 100 mg | Phase I: X-396 (Ensartinib) at 200 mg | Phase I: X-396 (Ensartinib) at 225 mg | Phase I: X-396 (Ensartinib) at 250 mg | Phase II: X-396 (Ensartinib) at 225 mg |
|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 5 | 11 | 4 | 10 | 94 |
| Completed | 4 | 3 | 5 | 11 | 4 | 10 | 94 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To evaluate the safety/tolerability of X-396 (ensartinib) and determine the maximum tolerated dose (MTD) of X-396 as a single agent.
| mg | Phase I/II X:396 Ensartinib |
|---|---|
| Maximum Tolerated Dose | 250 |
To explore the preliminary clinical tumor response after treatment with X-396 (ensartinib) given as a single agent in ALK positive patients at 225 mg QD. Subjects were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria (and CNS lesions were also assessed by modified Response Assessment in Neuro-Oncology). Assessments by CT or MRI were performed after every even cycle of treatment. All assessments were to be performed within 7 days of the scheduled day of assessment. Tumor lesions followed on physical examination must have been assessed on Day 1 of each cycle and at the End-of-Study Treatment Visit.
| participants | X-396 (Ensartinib) 225 mg |
|---|---|
| Number of Participants With Preliminary Tumor Response in ALK Positive Patients at 225 mg QD | 34 (31.1 to 53.5) |
To characterize the preliminary pharmacokinetics including Cmax f X-396 given as a single agent
| ng/ml | Phase I: X-396 (Ensartinib) at 25mg | Phase II: X-396 (Ensartinib) at 225 mg (Fasted) | Phase I: X-396 (Ensartinib) at 50 mg | Phase I: X-396 (Ensartinib) at 100 mg | Phase I: X-396 (Ensartinib) at 200 mg (Fasted) | Phase I: X-396 (Ensartinib) at 250mg | Phase I: X-396 (Ensartinib) at 225mg | Phase II: X-396 (Ensartinib) at 225 mg (Fed) | Phase I: X-396 (Ensartinib) at 200 mg (Fed) |
|---|---|---|---|---|---|---|---|---|---|
| Plasma Concentrations Cmax for Day 1 | 5 ± 81.9 | 136 ± 40.0 | 29 ± 86.5 | 53 ± 57.7 | 114 ± 79.8 | 182 ± 44.4 | 94 ± 44.0 | 125 ± 52.7 | 109 ± 44.5 |
To characterize the preliminary pharmacokinetics including T max of X-396 given as a single agent
| hour | Phase I: X-396 (Ensartinib) at 25mg | Phase II: X-396 (Ensartinib) at 225 mg (Fasted) | Phase I: X-396 (Ensartinib) at 50 mg | Phase I: X-396 (Ensartinib) at 100 mg | Phase I: X-396 (Ensartinib) at 200 mg (Fasted) | Phase I: X-396 (Ensartinib) at 250mg | Phase I: X-396 (Ensartinib) at 225mg | Phase II: X-396 (Ensartinib) at 225 mg (Fed) | Phase I: X-396 (Ensartinib) at 200 mg (Fed) |
|---|---|---|---|---|---|---|---|---|---|
| Plasma Tmax on Day 1 | 3.2 (2.25 to 6.00) | 3.2 (1.08 to 23.8) | 2.0 (1.00 to 6.00) | 3.0 (2.98 to 8.20) | 3.5 (2.03 to 8.23) | 3.1 (1.00 to 7.17) | 6.0 (2.37 to 8.00) | 4.0 (1.03 to 24.0) | 4.0 (3.00 to 6.00) |
To characterize the preliminary pharmacokinetics including AUC of X-396 given as a single agent
| h·ng/mL | Phase I: X-396 (Ensartinib) at 25mg | Phase II: X-396 (Ensartinib) at 225 mg (Fasted) | Phase I: X-396 (Ensartinib) at 50 mg | Phase I: X-396 (Ensartinib) at 100 mg | Phase I: X-396 (Ensartinib) at 200 mg (Fasted) | Phase I: X-396 (Ensartinib) at 250mg | Phase I: X-396 (Ensartinib) at 225mg | Phase II: X-396 (Ensartinib) at 225 mg (Fed) | Phase I: X-396 (Ensartinib) at 200 mg (Fed) |
|---|---|---|---|---|---|---|---|---|---|
| Plasma Concentrations AUC on Day 1 | 31 ± 39.0 | 756 ± 43.3 | 134 ± 71.2 | 250 ± 84.1 | 614 ± 66.8 | 973 ± 42.6 | 394 ± 74.9 | 664 ± 66.3 | 513 ± 28.3 |
To characterize the preliminary pharmacokinetics including half life of X-396 given as a single agent
| hour | Phase I: X-396 (Ensartinib) at 25mg | Phase II: X-396 (Ensartinib) at 225 mg (Fasted) | Phase I: X-396 (Ensartinib) at 50 mg | Phase I: X-396 (Ensartinib) at 100 mg | Phase I: X-396 (Ensartinib) at 200 mg (Fasted) | Phase I: X-396 (Ensartinib) at 250mg | Phase I: X-396 (Ensartinib) at 225mg | Phase II: X-396 (Ensartinib) at 225 mg (Fed) | Phase I: X-396 (Ensartinib) at 200 mg (Fed) |
|---|---|---|---|---|---|---|---|---|---|
| Plasma Concentrations Half-life on Day 1 | 0 ± 0 | 18 ± 52.1 | 0 ± 0 | 12 ± 17.5 | 18 ± 20.1 | 23 ± 55.2 | 0 ± 0 | 14 ± 9.18 | 0 ± 0 |
Collected over From first dose up to 30 days after the last dose of Ensartinib (up to 228 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I: X-396 (Ensartinib) at 25 mg | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Phase I: X-396 (Ensartinib) at 50 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase I: X-396 (Ensartinib) at 100 mg | 1/5 (20%) | 2/5 (40%) | 4/5 (80%) |
| Phase I: X-396 (Ensartinib) at 200 mg | 1/11 (9.1%) | 6/11 (54.5%) | 9/11 (81.8%) |
| Phase I: X-396 (Ensartinib) at 225 mg | 0/4 (0%) | 2/4 (50%) | 2/4 (50%) |
| Phase I: X-396 (Ensartinib) at 250 mg | 0/10 (0%) | 5/10 (50%) | 9/10 (90%) |
| Phase II: X-396 (Ensartinib) at 225 mg | 3/94 (3.2%) | 41/94 (43.6%) | 84/94 (89.4%) |
| Event | Phase I: X-396 (Ensartinib) at 25 mg | Phase I: X-396 (Ensartinib) at 50 mg | Phase I: X-396 (Ensartinib) at 100 mg | Phase I: X-396 (Ensartinib) at 200 mg | Phase I: X-396 (Ensartinib) at 225 mg | Phase I: X-396 (Ensartinib) at 250 mg | Phase II: X-396 (Ensartinib) at 225 mg |
|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/4 | 1/3 | 0/5 | 2/11 | 0/4 | 0/10 | 1/94 |
| Metabolism and connective tissue disordersMetabolism and nutrition disorders | 0/4 | 1/3 | 0/5 | 3/11 | 0/4 | 0/10 | 3/94 |
| Nervous system disordersNervous system disorders | 0/4 | 1/3 | 0/5 | 0/11 | 1/4 | 1/10 | 9/94 |
| Infections and infestationsInfections and infestations | 0/4 | 1/3 | 1/5 | 3/11 | 0/4 | 1/10 | 12/94 |
| Blood and lymphatic systemBlood and lymphatic system disorders | 1/4 | 0/3 | 0/5 | 0/11 | 0/4 | 0/10 | 3/94 |
| ConvulsionNervous system disorders | 0/4 | 0/3 | 0/5 | 0/11 | 1/4 | 1/10 | 3/94 |
| PneumoniaInfections and infestations | 0/4 | 0/3 | 1/5 | 2/11 | 0/4 | 0/10 | 4/94 |
| Cardiac disordersCardiac disorders | 0/4 | 0/3 | 0/5 | 1/11 | 0/4 | 1/10 | 7/94 |
| Muscoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 0/4 | 0/3 | 0/5 | 1/11 | 0/4 | 1/10 | 2/94 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/4 | 0/3 | 0/5 | 0/11 | 0/4 | 1/10 | 1/94 |
| Event | Phase I: X-396 (Ensartinib) at 25 mg | Phase I: X-396 (Ensartinib) at 50 mg | Phase I: X-396 (Ensartinib) at 100 mg | Phase I: X-396 (Ensartinib) at 200 mg | Phase I: X-396 (Ensartinib) at 225 mg | Phase I: X-396 (Ensartinib) at 250 mg | Phase II: X-396 (Ensartinib) at 225 mg |
|---|---|---|---|---|---|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 0/4 | 1/3 | 2/5 | 6/11 | 1/4 | 5/10 | 57/94 |
| VomitingGastrointestinal disorders | 0/4 | 1/3 | 0/5 | 4/11 | 1/4 | 5/10 | 24/94 |
| NauseaGastrointestinal disorders | 0/4 | 1/3 | 1/5 | 5/11 | 1/4 | 3/10 | 36/94 |
| Blood and lymphaticBlood and lymphatic system disorders | 1/4 | 0/3 | 1/5 | 0/11 | 0/4 | 0/10 | 11/94 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/3 | 1/5 | 0/11 | 0/4 | 0/10 | 8/94 |
| Blood Creatinine increasedInvestigations | 1/4 | 0/3 | 0/5 | 0/11 | 0/4 | 0/10 | 9/94 |
| Age, Categorical(Participants) | Phase I: X-396 (Ensartinib) 25 mg | Phase I: X-396 (Ensartinib) 50 mg | Phase I: X-396 (Ensartinib) 100 mg | Phase I: X-396 (Ensartinib) 200 mg | Phase I: X-396 (Ensartinib) 225 mg | Phase I: X-396 (Ensartinib) 250 mg | Phase II: X-396 (Ensartinib) 225 mg | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 3 | 5 | 11 | 4 | 10 | 94 | 131 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | Phase I: X-396 (Ensartinib) 25 mg | Phase I: X-396 (Ensartinib) 50 mg | Phase I: X-396 (Ensartinib) 100 mg | Phase I: X-396 (Ensartinib) 200 mg | Phase I: X-396 (Ensartinib) 225 mg | Phase I: X-396 (Ensartinib) 250 mg | Phase II: X-396 (Ensartinib) 225 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 53.5 ± 7.33 | 57.7 ± 16.20 | 56.2 ± 4.87 | 57.5 ± 14.05 | 60.0 ± 12.25 | 55.4 ± 11.58 | 56.0 ± 13.59 | 56.2 ± 12.92 |
| Sex: Female, Male(Participants) | Phase I: X-396 (Ensartinib) 25 mg | Phase I: X-396 (Ensartinib) 50 mg | Phase I: X-396 (Ensartinib) 100 mg | Phase I: X-396 (Ensartinib) 200 mg | Phase I: X-396 (Ensartinib) 225 mg | Phase I: X-396 (Ensartinib) 250 mg | Phase II: X-396 (Ensartinib) 225 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 2 | 5 | 2 | 6 | 46 | 64 |
| Male | 2 | 2 | 3 | 6 | 2 | 4 | 48 | 67 |
| Race (NIH/OMB)(Participants) | Phase I: X-396 (Ensartinib) 25 mg | Phase I: X-396 (Ensartinib) 50 mg | Phase I: X-396 (Ensartinib) 100 mg | Phase I: X-396 (Ensartinib) 200 mg | Phase I: X-396 (Ensartinib) 225 mg | Phase I: X-396 (Ensartinib) 250 mg | Phase II: X-396 (Ensartinib) 225 mg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 18 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 0 | 0 | 0 | 4 | 7 |
| White | 3 | 2 | 4 | 10 | 4 | 10 | 65 | 98 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 |
| Region of Enrollment(participants) | Phase I: X-396 (Ensartinib) 25 mg | Phase I: X-396 (Ensartinib) 50 mg | Phase I: X-396 (Ensartinib) 100 mg | Phase I: X-396 (Ensartinib) 200 mg | Phase I: X-396 (Ensartinib) 225 mg | Phase I: X-396 (Ensartinib) 250 mg | Phase II: X-396 (Ensartinib) 225 mg | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 4 | 3 | 5 | 11 | 4 | 10 | 94 | 131 |
| ECOG Performance Status(# of patients with Score Grade (0-5)) | Phase I: X-396 (Ensartinib) 25 mg | Phase I: X-396 (Ensartinib) 50 mg | Phase I: X-396 (Ensartinib) 100 mg | Phase I: X-396 (Ensartinib) 200 mg | Phase I: X-396 (Ensartinib) 225 mg | Phase I: X-396 (Ensartinib) 250 mg | Phase II: X-396 (Ensartinib) 225 mg | Total |
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 0 | 3 | 6 | 2 | 4 | 29 | 45 |
| 1 | 3 | 3 | 2 | 5 | 2 | 6 | 63 | 84 |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not Determined | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Tobacco user(Participants) | Phase I: X-396 (Ensartinib) 25 mg | Phase I: X-396 (Ensartinib) 50 mg | Phase I: X-396 (Ensartinib) 100 mg | Phase I: X-396 (Ensartinib) 200 mg | Phase I: X-396 (Ensartinib) 225 mg | Phase I: X-396 (Ensartinib) 250 mg | Phase II: X-396 (Ensartinib) 225 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Never | 2 | 1 | 2 | 5 | 3 | 8 | 57 | 78 |
| Former | 2 | 2 | 1 | 5 | 1 | 2 | 36 | 49 |
| Current | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jun 2012, a primary completion of Sep 2020 and a completion of Sep 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2026, 5 years 7 months after primary completion. A results delay was requested in Sep 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensartinib
Carcinoma, Non-Small-Cell Lung →